MAPT and Alzheimer disease: Supporting this notion, the finding of higher levels of tau and NF-L proteins in both plasma and cerebrospinal fluid (CSF) in CJD and AD patients suggests the possibility of using the detection of plasma cytoskeleton proteins as a tool to detect neurodegeneration, and to contribute and support early diagnosis and the identification of disease subtypes [267].